{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:05:46Z","timestamp":1781651146367,"version":"3.54.5"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Interdisciplinary Research Project of Hangzhou Normal University","award":["2024JCXK02"],"award-info":[{"award-number":["2024JCXK02"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science and Foundation of China","doi-asserted-by":"crossref","award":["82241037"],"award-info":[{"award-number":["82241037"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science and Foundation of China","doi-asserted-by":"crossref","award":["82170725"],"award-info":[{"award-number":["82170725"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004479","name":"Jiangxi Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["20242BAB26114"],"award-info":[{"award-number":["20242BAB26114"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LZ25H190001"],"award-info":[{"award-number":["LZ25H190001"]}]},{"name":"Pioneer and Leading Goose R&D Program of Zhejiang","award":["2023C03096"],"award-info":[{"award-number":["2023C03096"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40259-025-00740-2","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T08:32:10Z","timestamp":1759393930000},"page":"899-922","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria"],"prefix":"10.1007","volume":"39","author":[{"given":"Yuanzhi","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxi","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuping","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"740_CR1","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629\u201355.","journal-title":"Lancet"},{"key":"740_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.semcdb.2018.05.026","volume":"88","author":"W Lu","year":"2019","unstructured":"Lu W. Antimicrobial peptides. Semin Cell Dev Biol. 2019;88:105\u20136.","journal-title":"Semin Cell Dev Biol"},{"key":"740_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fchem.2019.00043","volume":"7","author":"EF Haney","year":"2019","unstructured":"Haney EF, Straus SK, Hancock REW. Reassessing the host defense peptide landscape. Front Chem. 2019;7:43.","journal-title":"Front Chem"},{"key":"740_CR4","doi-asserted-by":"publisher","first-page":"eaau5480","DOI":"10.1126\/science.aau5480","volume":"368","author":"BP Lazzaro","year":"2020","unstructured":"Lazzaro BP, Zasloff M, Rolff J. Antimicrobial peptides: application informed by evolution. Science. 2020;368:eaau5480.","journal-title":"Science"},{"key":"740_CR5","unstructured":"Antimicrobial peptide database [Internet]. https:\/\/aps.unmc.edu\/AP\/. Accessed 24 Apr 2025."},{"key":"740_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrmicro2745","volume":"10","author":"REW Hancock","year":"2012","unstructured":"Hancock REW, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol. 2012;10:243\u201354.","journal-title":"Nat Rev Microbiol"},{"key":"740_CR7","volume":"8","author":"Q-Y Zhang","year":"2021","unstructured":"Zhang Q-Y, Yan Z-B, Meng Y-M, Hong X-Y, Shao G, Ma J-J, et al. Antimicrobial peptides: mechanism of action, activity and clinical potential. Mil Med Res. 2021;8:48.","journal-title":"Mil Med Res"},{"key":"740_CR8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.3390\/molecules30071529","volume":"30","author":"H Zhang","year":"2025","unstructured":"Zhang H, Lv J, Ma Z, Ma J, Chen J. Advances in antimicrobial peptides: mechanisms, design innovations, and biomedical potential. Molecules. 2025;30:1529.","journal-title":"Molecules"},{"key":"740_CR9","doi-asserted-by":"publisher","first-page":"11401","DOI":"10.3390\/ijms222111401","volume":"22","author":"Y Luo","year":"2021","unstructured":"Luo Y, Song Y. Mechanism of antimicrobial peptides: antimicrobial, anti-inflammatory and antibiofilm activities. Int J Mol Sci. 2021;22:11401.","journal-title":"Int J Mol Sci"},{"key":"740_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jcis.2018.10.103","volume":"537","author":"D Ciumac","year":"2019","unstructured":"Ciumac D, Gong H, Hu X, Lu JR. Membrane targeting cationic antimicrobial peptides. J Colloid Interface Sci. 2019;537:163\u201385.","journal-title":"J Colloid Interface Sci"},{"key":"740_CR11","doi-asserted-by":"publisher","first-page":"e0057824","DOI":"10.1128\/mbio.00578-24","volume":"15","author":"A Berscheid","year":"2024","unstructured":"Berscheid A, Straetener J, Schilling NA, Ruppelt D, Konnerth MC, Schittek B, et al. The microbiome-derived antibacterial lugdunin acts as a cation ionophore in synergy with host peptides. MBio. 2024;15:e0057824.","journal-title":"MBio"},{"key":"740_CR12","doi-asserted-by":"publisher","first-page":"20891","DOI":"10.1021\/jacs.4c05377","volume":"146","author":"VR Koynarev","year":"2024","unstructured":"Koynarev VR, Borgos KKA, Kohlbrecher J, Porcar L, Nielsen JE, Lund R. Antimicrobial peptides increase line tension in raft-forming lipid membranes. J Am Chem Soc. 2024;146:20891\u2013903.","journal-title":"J Am Chem Soc"},{"key":"740_CR13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.24272\/j.issn.2095-8137.2019.062","volume":"40","author":"J Mwangi","year":"2019","unstructured":"Mwangi J, Hao X, Lai R, Zhang Z-Y. Antimicrobial peptides: new hope in the war against multidrug resistance. Zool Res. 2019;40:488\u2013505.","journal-title":"Zool Res"},{"key":"740_CR14","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41586-025-08723-7","volume":"640","author":"M Jangra","year":"2025","unstructured":"Jangra M, Travin DY, Aleksandrova EV, Kaur M, Darwish L, Koteva K, et al. A broad-spectrum lasso peptide antibiotic targeting the bacterial ribosome. Nature. 2025;640:1022\u201330.","journal-title":"Nature"},{"key":"740_CR15","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s12033-021-00325-8","volume":"63","author":"F Hemmati","year":"2021","unstructured":"Hemmati F, Rezaee MA, Ebrahimzadeh S, Yousefi L, Nouri R, Kafil HS, et al. Novel strategies to combat bacterial biofilms. Mol Biotechnol. 2021;63:569\u201386.","journal-title":"Mol Biotechnol"},{"key":"740_CR16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1080\/21505594.2017.1313372","volume":"9","author":"R Roy","year":"2018","unstructured":"Roy R, Tiwari M, Donelli G, Tiwari V. Strategies for combating bacterial biofilms: a focus on anti-biofilm agents and their mechanisms of action. Virulence. 2018;9:522\u201354.","journal-title":"Virulence"},{"key":"740_CR17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s10096-015-2323-z","volume":"34","author":"I Olsen","year":"2015","unstructured":"Olsen I. Biofilm-specific antibiotic tolerance and resistance. Eur J Clin Microbiol Infect Dis. 2015;34:877\u201386.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"740_CR18","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3389\/fchem.2019.00824","volume":"7","author":"AD Verderosa","year":"2019","unstructured":"Verderosa AD, Totsika M, Fairfull-Smith KE. Bacterial biofilm eradication agents: a current review. Front Chem. 2019;7:824.","journal-title":"Front Chem"},{"key":"740_CR19","doi-asserted-by":"publisher","first-page":"27866","DOI":"10.1021\/acsami.0c00771","volume":"12","author":"J Zhang","year":"2020","unstructured":"Zhang J, Chen C, Chen J, Zhou S, Zhao Y, Xu M, et al. Dual mode of anti-biofilm action of G3 against streptococcus mutans. ACS Appl Mater Interfaces. 2020;12:27866\u201375.","journal-title":"ACS Appl Mater Interfaces"},{"key":"740_CR20","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.3389\/fmicb.2017.01867","volume":"8","author":"D Pletzer","year":"2017","unstructured":"Pletzer D, Wolfmeier H, Bains M, Hancock REW. Synthetic peptides to target stringent response-controlled virulence in a pseudomonas aeruginosa murine cutaneous infection model. Front Microbiol. 2017;8:1867.","journal-title":"Front Microbiol"},{"key":"740_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jss.2012.11.048","volume":"183","author":"C Zhu","year":"2013","unstructured":"Zhu C, Tan H, Cheng T, Shen H, Shao J, Guo Y, et al. Human \u03b2-defensin 3 inhibits antibiotic-resistant staphylococcus biofilm formation. J Surg Res. 2013;183:204\u201313.","journal-title":"J Surg Res"},{"key":"740_CR22","doi-asserted-by":"publisher","first-page":"4176","DOI":"10.1128\/IAI.00318-08","volume":"76","author":"J Overhage","year":"2008","unstructured":"Overhage J, Campisano A, Bains M, Torfs ECW, Rehm BHA, Hancock REW. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun. 2008;76:4176\u201382.","journal-title":"Infect Immun"},{"key":"740_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2025.108570","volume":"81","author":"R Yang","year":"2025","unstructured":"Yang R, Ma X, Peng F, Wen J, Allahou LW, Williams GR, et al. Advances in antimicrobial peptides: from mechanistic insights to chemical modifications. Biotechnol Adv. 2025;81:108570.","journal-title":"Biotechnol Adv"},{"key":"740_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.70.1.1","volume":"70","author":"RJ Dubos","year":"1939","unstructured":"Dubos RJ. Studies on a bactericidal agent extracted from a soil bacillus\u202f: I. Preparation of the agent. Its activity in vitro. J Exp Med. 1939;70:1\u201310.","journal-title":"J Exp Med"},{"key":"740_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1084\/jem.70.1.11","volume":"70","author":"RJ Dubos","year":"1939","unstructured":"Dubos RJ. Studies on a bactericidal agent extracted from a soil bacillus\u202f: Ii. protective effect of the bactericidal agent against experimental pneumococcus infections in mice. J Exp Med. 1939;70:11\u20137.","journal-title":"J Exp Med"},{"key":"740_CR26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1084\/jem.70.3.249","volume":"70","author":"RJ Dubos","year":"1939","unstructured":"Dubos RJ, Cattaneo C. Studies on a bactericidal agent extracted from a soil bacillus\u202f: III. Preparation and activity of a protein-free fraction. J Exp Med. 1939;70:249\u201356.","journal-title":"J Exp Med"},{"key":"740_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.12864","volume":"43","author":"K Jiao","year":"2019","unstructured":"Jiao K, Gao J, Zhou T, Yu J, Song H, Wei Y, et al. Isolation and purification of a novel antimicrobial peptide from porphyra yezoensis. J Food Biochem. 2019;43:e12864.","journal-title":"J Food Biochem"},{"key":"740_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2021.101229","volume":"39","author":"P Tan","year":"2021","unstructured":"Tan P, Fu H, Ma X. Design, optimization, and nanotechnology of antimicrobial peptides: from exploration to applications. Nano Today. 2021;39:101229.","journal-title":"Nano Today"},{"key":"740_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/1751-7915.14213","volume":"16","author":"MG Ciulla","year":"2023","unstructured":"Ciulla MG, Gelain F. Structure-activity relationships of antibacterial peptides. Microb Biotechnol. 2023;16:757\u201377.","journal-title":"Microb Biotechnol"},{"key":"740_CR30","doi-asserted-by":"crossref","unstructured":"Guevara YAS, Santos MHC, Gomes FIR, Sheheryar, Mesquita FP, Souza PFN. A historical, economic, and technical-scientific approach to the current crisis in the development of antibacterial drugs: Promising role of antibacterial peptides in this scenario. Microb Pathog. 2023;179:106108.","DOI":"10.1016\/j.micpath.2023.106108"},{"key":"740_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41586-019-1665-6","volume":"576","author":"A Luther","year":"2019","unstructured":"Luther A, Urfer M, Zahn M, M\u00fcller M, Wang S-Y, Mondal M, et al. Chimeric peptidomimetic antibiotics against gram-negative bacteria. Nature. 2019;576:452\u20138.","journal-title":"Nature"},{"key":"740_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.563030","volume":"11","author":"J Lu","year":"2020","unstructured":"Lu J, Xu H, Xia J, Ma J, Xu J, Li Y, et al. D- and unnatural amino acid substituted antimicrobial peptides with improved proteolytic resistance and their proteolytic degradation characteristics. Front Microbiol. 2020;11:563030.","journal-title":"Front Microbiol"},{"key":"740_CR33","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s42003-022-03899-4","volume":"5","author":"J Shi","year":"2022","unstructured":"Shi J, Chen C, Wang D, Wang Z, Liu Y. The antimicrobial peptide LI14 combats multidrug-resistant bacterial infections. Commun Biol. 2022;5:926.","journal-title":"Commun Biol"},{"key":"740_CR34","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.biomaterials.2010.11.054","volume":"32","author":"N Wiradharma","year":"2011","unstructured":"Wiradharma N, Khoe U, Hauser CAE, Seow SV, Zhang S, Yang Y-Y. Synthetic cationic amphiphilic \u03b1-helical peptides as antimicrobial agents. Biomaterials. 2011;32:2204\u201312.","journal-title":"Biomaterials"},{"key":"740_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2023.102733","volume":"83","author":"P Szymczak","year":"2023","unstructured":"Szymczak P, Szczurek E. Artificial intelligence-driven antimicrobial peptide discovery. Curr Opin Struct Biol. 2023;83:102733.","journal-title":"Curr Opin Struct Biol"},{"key":"740_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.biomaterials.2016.02.011","volume":"87","author":"L Ma","year":"2016","unstructured":"Ma L, Wang Y, Wang M, Tian Y, Kang W, Liu H, et al. Effective antimicrobial activity of CBF-14, derived from a cathelin-like domain, against penicillin-resistant bacteria. Biomaterials. 2016;87:32\u201345.","journal-title":"Biomaterials"},{"key":"740_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41392-024-01895-0","volume":"9","author":"X Guo","year":"2024","unstructured":"Guo X, Zhao X, Lu X, Zhao L, Zeng Q, Chen F, et al. A deep learning-driven discovery of berberine derivatives as novel antibacterial against multidrug-resistant helicobacter pylori. Signal Transduct Target Ther. 2024;9:183.","journal-title":"Signal Transduct Target Ther"},{"key":"740_CR38","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1016\/j.cell.2024.07.027","volume":"187","author":"MDT Torres","year":"2024","unstructured":"Torres MDT, Brooks EF, Cesaro A, Sberro H, Gill MO, Nicolaou C, et al. Mining human microbiomes reveals an untapped source of peptide antibiotics. Cell. 2024;187:5453-5467.e15.","journal-title":"Cell"},{"key":"740_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1586\/eri.13.12","volume":"11","author":"JN Pendleton","year":"2013","unstructured":"Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti-Infect Ther. 2013;11:297\u2013308.","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"740_CR40","doi-asserted-by":"publisher","first-page":"2475067","DOI":"10.1155\/2016\/2475067","volume":"2016","author":"S Santajit","year":"2016","unstructured":"Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed Res Int. 2016;2016:2475067.","journal-title":"Biomed Res Int"},{"key":"740_CR41","unstructured":"WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed 24 Apr 2025."},{"key":"740_CR42","unstructured":"WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance [Internet]. https:\/\/www.who.int\/publications\/i\/item\/9789240093461. Accessed 24 Apr 2025."},{"key":"740_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117518","volume":"290","author":"W Dan","year":"2025","unstructured":"Dan W, Xiong Y, Li R, Gao H, Liu P, Sui M, et al. Synthesis and anti-MRSA activity of quaternized small molecule antimicrobial peptide mimics based on norharmane. Eur J Med Chem. 2025;290:117518.","journal-title":"Eur J Med Chem"},{"key":"740_CR44","doi-asserted-by":"crossref","unstructured":"Vestergaard M, Frees D, Ingmer H. Antibiotic resistance and the MRSA problem. Microbiol Spectr. 2019;7(2): GPP3-0057-2018.","DOI":"10.1128\/microbiolspec.GPP3-0057-2018"},{"key":"740_CR45","doi-asserted-by":"publisher","first-page":"12426","DOI":"10.1021\/ja305644e","volume":"134","author":"B Mishra","year":"2012","unstructured":"Mishra B, Wang G. Ab initio design of potent anti-MRSA peptides based on database filtering technology. J Am Chem Soc. 2012;134:12426\u20139.","journal-title":"J Am Chem Soc"},{"key":"740_CR46","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1128\/AAC.02578-14","volume":"58","author":"MF Mohamed","year":"2014","unstructured":"Mohamed MF, Hamed MI, Panitch A, Seleem MN. Targeting methicillin-resistant staphylococcus aureus with short salt-resistant synthetic peptides. Antimicrob Agents Chemother. 2014;58:4113\u201322.","journal-title":"Antimicrob Agents Chemother"},{"key":"740_CR47","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1021\/acs.jmedchem.3c01360","volume":"67","author":"C Li","year":"2024","unstructured":"Li C, Zhou Z, Wang W, Zhao Y, Yin X, Meng Y, et al. Development of antibacterial peptides with membrane disruption and folate pathway inhibitory activities against methicillin-resistant staphylococcus aureus. J Med Chem. 2024;67:1044\u201360.","journal-title":"J Med Chem"},{"issue":"24","key":"740_CR48","first-page":"00036","volume":"S2090\u20131232","author":"B Xu","year":"2024","unstructured":"Xu B, Wang L, Yang C, Yan R, Zhang P, Jin M, et al. Specifically targeted antimicrobial peptides synergize with bacterial-entrapping peptide against systemic MRSA infections. J Adv Res. 2024;S2090\u20131232(24):00036\u201345.","journal-title":"J Adv Res"},{"key":"740_CR49","doi-asserted-by":"crossref","unstructured":"Luo X-Y, Hu C-M, Yin Q, Zhang X-M, Liu Z-Z, Zhou C-K, et al. Dual-mechanism peptide SR25 has broad antimicrobial activity and potential application for healing bacteria-infected diabetic wounds. Adv Sci (Weinh). 2024;11:e2401793.","DOI":"10.1002\/advs.202401793"},{"key":"740_CR50","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1574-6976.2012.00344.x","volume":"37","author":"MJ McConnell","year":"2013","unstructured":"McConnell MJ, Actis L, Pach\u00f3n J. Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol Rev. 2013;37:130\u201355.","journal-title":"FEMS Microbiol Rev"},{"key":"740_CR51","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1007\/s11033-021-06690-6","volume":"48","author":"S Ibrahim","year":"2021","unstructured":"Ibrahim S, Al-Saryi N, Al-Kadmy IMS, Aziz SN. Multidrug-resistant acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep. 2021;48:6987\u201398.","journal-title":"Mol Biol Rep"},{"key":"740_CR52","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11274-023-03545-z","volume":"39","author":"H Memariani","year":"2023","unstructured":"Memariani H, Memariani M. Antibiofilm properties of cathelicidin LL-37: an in-depth review. World J Microbiol Biotechnol. 2023;39:99.","journal-title":"World J Microbiol Biotechnol"},{"key":"740_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.peptides.2013.09.007","volume":"49","author":"X Feng","year":"2013","unstructured":"Feng X, Sambanthamoorthy K, Palys T, Paranavitana C. The human antimicrobial peptide LL-37 and its fragments possess both antimicrobial and antibiofilm activities against multidrug-resistant Acinetobacter baumannii. Peptides. 2013;49:131\u20137.","journal-title":"Peptides"},{"key":"740_CR54","doi-asserted-by":"publisher","first-page":"6216","DOI":"10.3390\/ijms21176216","volume":"21","author":"M Krishnan","year":"2020","unstructured":"Krishnan M, Choi J, Jang A, Kim Y. A novel peptide antibiotic, Pro10-1D, designed from insect defensin shows antibacterial and anti-inflammatory activities in sepsis models. Int J Mol Sci. 2020;21:6216.","journal-title":"Int J Mol Sci"},{"key":"740_CR55","doi-asserted-by":"publisher","first-page":"26516","DOI":"10.1073\/pnas.1909585117","volume":"116","author":"J Mwangi","year":"2019","unstructured":"Mwangi J, Yin Y, Wang G, Yang M, Li Y, Zhang Z, et al. The antimicrobial peptide ZY4 combats multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii infection. Proc Natl Acad Sci USA. 2019;116:26516\u201322.","journal-title":"Proc Natl Acad Sci USA"},{"key":"740_CR56","first-page":"39","volume":"13","author":"ML van Hoek","year":"2023","unstructured":"van Hoek ML, Alsaab FM, Carpenter AM. GATR-3, a peptide that eradicates preformed biofilms of multidrug-resistant acinetobacter baumannii. Anitibiotics-Basel. 2023;13:39.","journal-title":"Anitibiotics-Basel."},{"key":"740_CR57","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1038\/s41598-021-86155-9","volume":"11","author":"S Mandel","year":"2021","unstructured":"Mandel S, Michaeli J, Nur N, Erbetti I, Zazoun J, Ferrari L, et al. OMN6 a novel bioengineered peptide for the treatment of multidrug resistant gram negative bacteria. Sci Rep. 2021;11:6603.","journal-title":"Sci Rep"},{"key":"740_CR58","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212527","volume":"7","author":"M Bassetti","year":"2018","unstructured":"Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage pseudomonas aeruginosa infections. Drugs Context. 2018;7:212527.","journal-title":"Drugs Context"},{"key":"740_CR59","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","volume":"37","author":"Z Pang","year":"2019","unstructured":"Pang Z, Raudonis R, Glick BR, Lin T-J, Cheng Z. Antibiotic resistance in pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37:177\u201392.","journal-title":"Biotechnol Adv"},{"key":"740_CR60","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1128\/AAC.50.2.806-809.2006","volume":"50","author":"G Maisetta","year":"2006","unstructured":"Maisetta G, Batoni G, Esin S, Florio W, Bottai D, Favilli F, et al. In vitro bactericidal activity of human beta-defensin 3 against multidrug-resistant nosocomial strains. Antimicrob Agents Chemother. 2006;50:806\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"740_CR61","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1182749","volume":"327","author":"N Srinivas","year":"2010","unstructured":"Srinivas N, Jetter P, Ueberbacher BJ, Werneburg M, Zerbe K, Steinmann J, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in pseudomonas aeruginosa. Science. 2010;327:1010\u20133.","journal-title":"Science"},{"key":"740_CR62","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00031-19","volume":"32","author":"JP Horcajada","year":"2019","unstructured":"Horcajada JP, Montero M, Oliver A, Sorl\u00ed L, Luque S, G\u00f3mez-Zorrilla S, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32:e00031\u201319.","journal-title":"Clin Microbiol Rev"},{"key":"740_CR63","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41573-023-00791-6","volume":"22","author":"U Theuretzbacher","year":"2023","unstructured":"Theuretzbacher U, Blasco B, Duffey M, Piddock LJV. Unrealized targets in the discovery of antibiotics for gram-negative bacterial infections. Nat Rev Drug Discov. 2023;22:957\u201375.","journal-title":"Nat Rev Drug Discov"},{"key":"740_CR64","doi-asserted-by":"publisher","first-page":"6953","DOI":"10.1038\/s41598-017-07440-0","volume":"7","author":"MF Mohamed","year":"2017","unstructured":"Mohamed MF, Brezden A, Mohammad H, Chmielewski J, Seleem MN. A short D-enantiomeric antimicrobial peptide with potent immunomodulatory and antibiofilm activity against multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Sci Rep. 2017;7:6953.","journal-title":"Sci Rep"},{"key":"740_CR65","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ijantimicag.2018.04.019","volume":"52","author":"Q Lin","year":"2018","unstructured":"Lin Q, Deslouches B, Montelaro RC, Di YP. Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37. Int J Antimicrob Agents. 2018;52:667\u201372.","journal-title":"Int J Antimicrob Agents"},{"key":"740_CR66","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12866-023-02886-x","volume":"23","author":"S Masihzadeh","year":"2023","unstructured":"Masihzadeh S, Amin M, Farshadzadeh Z. In vitro and in vivo antibiofilm activity of the synthetic antimicrobial peptide WLBU2 against multiple drug resistant Pseudomonas aeruginosa strains. BMC Microbiol. 2023;23:131.","journal-title":"BMC Microbiol"},{"key":"740_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay6817","volume":"6","author":"YP Di","year":"2020","unstructured":"Di YP, Lin Q, Chen C, Montelaro RC, Doi Y, Deslouches B. Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria. Sci Adv. 2020;6:eaay6817.","journal-title":"Sci Adv"},{"key":"740_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111814","volume":"185","author":"H Kim","year":"2020","unstructured":"Kim H, Jang JH, Kim SC, Cho JH. Development of a novel hybrid antimicrobial peptide for targeted killing of Pseudomonas aeruginosa. Eur J Med Chem. 2020;185:111814.","journal-title":"Eur J Med Chem"},{"key":"740_CR69","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1128\/AAC.01497-10","volume":"55","author":"M Castanheira","year":"2011","unstructured":"Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early dissemination of NDM-1- and OXA-181-producing enterobacteriaceae in Indian hospitals: report from the SENTRY antimicrobial surveillance program, 2006\u20132007. Antimicrob Agents Chemother. 2011;55:1274\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"740_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101031","volume":"72","author":"Y Li","year":"2024","unstructured":"Li Y, Sun X, Dong N, Wang Z, Li R. Global distribution and genomic characteristics of carbapenemase-producing escherichia coli among humans, 2005\u20132023. Drug Resist Updat. 2024;72:101031.","journal-title":"Drug Resist Updat"},{"key":"740_CR71","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jgar.2023.09.001","volume":"35","author":"J Kong","year":"2023","unstructured":"Kong J, Wang Y, Han Y, Zhou H, Huang Z, Zhang X, et al. Octominin: an antimicrobial peptide with antibacterial and anti-inflammatory activity against carbapenem-resistant escherichia coli both in vitro and in vivo. J Glob Antimicrob Resist. 2023;35:172\u201380.","journal-title":"J Glob Antimicrob Resist"},{"key":"740_CR72","doi-asserted-by":"publisher","first-page":"9104","DOI":"10.3390\/ijms21239104","volume":"21","author":"M Makowski","year":"2020","unstructured":"Makowski M, Fel\u00edcio MR, Fensterseifer ICM, Franco OL, Santos NC, Gon\u00e7alves S. EcDBS1R4, an antimicrobial peptide effective against Escherichia coli with in vitro fusogenic ability. Int J Mol Sci. 2020;21:9104.","journal-title":"Int J Mol Sci"},{"key":"740_CR73","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41564-024-01907-3","volume":"10","author":"B Wang","year":"2025","unstructured":"Wang B, Lin P, Zhong Y, Tan X, Shen Y, Huang Y, et al. Explainable deep learning and virtual evolution identifies antimicrobial peptides with activity against multidrug-resistant human pathogens. Nat Microbiol. 2025;10:332\u201347.","journal-title":"Nat Microbiol"},{"key":"740_CR74","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1038\/s41467-019-11503-3","volume":"10","author":"B Ma","year":"2019","unstructured":"Ma B, Fang C, Lu L, Wang M, Xue X, Zhou Y, et al. The antimicrobial peptide thanatin disrupts the bacterial outer membrane and inactivates the NDM-1 metallo-\u03b2-lactamase. Nat Commun. 2019;10:3517.","journal-title":"Nat Commun"},{"key":"740_CR75","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1038\/s41467-020-16950-x","volume":"11","author":"AG Elliott","year":"2020","unstructured":"Elliott AG, Huang JX, Neve S, Zuegg J, Edwards IA, Cain AK, et al. An amphipathic peptide with antibiotic activity against multidrug-resistant gram-negative bacteria. Nat Commun. 2020;11:3184.","journal-title":"Nat Commun"},{"key":"740_CR76","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00517-20","volume":"64","author":"H Van Der Weide","year":"2020","unstructured":"Van Der Weide H, Coss\u00edo U, Gracia R, Te Welscher YM, Ten Kate MT, Van Der Meijden A, et al. Therapeutic efficacy of novel antimicrobial peptide AA139-nanomedicines in a multidrug-resistant Klebsiella pneumoniae pneumonia-septicemia model in rats. Antimicrob Agents Chemother. 2020;64:e00517\u201320.","journal-title":"Antimicrob Agents Chemother"},{"key":"740_CR77","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.bbamem.2018.08.001","volume":"1861","author":"LN Irazazabal","year":"2019","unstructured":"Irazazabal LN, Porto WF, Fensterseifer ICM, Alves ESF, Matos CO, Menezes ACS, et al. Fast and potent bactericidal membrane lytic activity of PaDBS1R1, a novel cationic antimicrobial peptide. Biochim Biophys Acta (BBA) Biomembr. 2019;1861:178\u201390.","journal-title":"Biochim Biophys Acta (BBA) Biomembr"},{"key":"740_CR78","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.tips.2021.12.006","volume":"43","author":"CM de Souza","year":"2022","unstructured":"de Souza CM, da Silva \u00c1P, J\u00fanior NGO, Mart\u00ednez OF, Franco OL. Peptides as a therapeutic strategy against Klebsiella pneumoniae. Trends Pharmacol Sci. 2022;43:335\u201348.","journal-title":"Trends Pharmacol Sci"},{"key":"740_CR79","doi-asserted-by":"publisher","first-page":"46590","DOI":"10.1074\/jbc.M308615200","volume":"278","author":"L Bracci","year":"2003","unstructured":"Bracci L, Falciani C, Lelli B, Lozzi L, Runci Y, Pini A, et al. Synthetic peptides in the form of dendrimers become resistant to protease activity. J Biol Chem. 2003;278:46590\u20135.","journal-title":"J Biol Chem"},{"key":"740_CR80","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ijantimicag.2019.05.019","volume":"54","author":"H Van Der Weide","year":"2019","unstructured":"Van Der Weide H, Vermeulen-de Jongh DMC, Van Der Meijden A, Boers SA, Kreft D, Ten Kate MT, et al. Antimicrobial activity of two novel antimicrobial peptides AA139 and SET-M33 against clinically and genotypically diverse klebsiella pneumoniae isolates with differing antibiotic resistance profiles. Int J Antimicrob Agents. 2019;54:159\u201366.","journal-title":"Int J Antimicrob Agents"},{"key":"740_CR81","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1021\/acsinfecdis.9b00164","volume":"6","author":"Y Liu","year":"2020","unstructured":"Liu Y, Jia Y, Yang K, Li R, Xiao X, Wang Z. Antagonizing vancomycin resistance in enterococcus by surface localized antimicrobial display-derived peptides. ACS Infect Dis. 2020;6:761\u20137.","journal-title":"ACS Infect Dis"},{"key":"740_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046259","volume":"7","author":"C Falciani","year":"2012","unstructured":"Falciani C, Lozzi L, Pollini S, Luca V, Carnicelli V, Brunetti J, et al. Isomerization of an antimicrobial peptide broadens antimicrobial spectrum to gram-positive bacterial pathogens. PLoS ONE. 2012;7:e46259.","journal-title":"PLoS ONE"},{"key":"740_CR83","doi-asserted-by":"publisher","first-page":"26077","DOI":"10.1038\/srep26077","volume":"6","author":"J Brunetti","year":"2016","unstructured":"Brunetti J, Falciani C, Roscia G, Pollini S, Bindi S, Scali S, et al. In vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate. Sci Rep. 2016;6:26077.","journal-title":"Sci Rep"},{"key":"740_CR84","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nature14098","volume":"517","author":"LL Ling","year":"2015","unstructured":"Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP, et al. A new antibiotic kills pathogens without detectable resistance. Nature. 2015;517:455\u20139.","journal-title":"Nature"},{"key":"740_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115853","volume":"261","author":"A Parmar","year":"2023","unstructured":"Parmar A, Lakshminarayanan R, Iyer A, Goh ETL, To TY, Yam JKH, et al. Development of teixobactin analogues containing hydrophobic, non-proteogenic amino acids that are highly potent against multidrug-resistant bacteria and biofilms. Eur J Med Chem. 2023;261:115853.","journal-title":"Eur J Med Chem"},{"key":"740_CR86","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/toxins15040268","volume":"15","author":"WG Lima","year":"2023","unstructured":"Lima WG, de Lima ME. Therapeutic prospection of animal venoms-derived antimicrobial peptides against infections by multidrug-resistant Acinetobacter baumannii: a systematic review of pre-clinical studies. Toxins. 2023;15:268.","journal-title":"Toxins"},{"key":"740_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.pep.2024.106475","volume":"219","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang Y, Lu J, Huang Z, Hua H, Li Y, et al. High-yield and cost-effective biosynthesis process for producing antimicrobial peptide AA139. Protein Expr Purif. 2024;219:106475.","journal-title":"Protein Expr Purif"},{"key":"740_CR88","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1021\/acssynbio.7b00396","volume":"7","author":"J Cao","year":"2018","unstructured":"Cao J, de la Fuente-Nunez C, Ou RW, Torres MDT, Pande SG, Sinskey AJ, et al. Yeast-based synthetic biology platform for antimicrobial peptide production. ACS Synth Biol. 2018;7:896\u2013902.","journal-title":"ACS Synth Biol"},{"key":"740_CR89","doi-asserted-by":"publisher","first-page":"7197","DOI":"10.1038\/s41467-023-42434-9","volume":"14","author":"A Pandi","year":"2023","unstructured":"Pandi A, Adam D, Zare A, Trinh VT, Schaefer SL, Burt M, et al. Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides. Nat Commun. 2023;14:7197.","journal-title":"Nat Commun"},{"key":"740_CR90","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw275","volume":"4","author":"V Boix","year":"2017","unstructured":"Boix V, Fedorak RN, Mullane KM, Pesant Y, Stoutenburgh U, Jin M, et al. Primary outcomes from a phase 3, randomized, double-blind, active-controlled trial of surotomycin in subjects with Clostridium difficile infection. Open Forum Infect Dis. 2017;4:ofw275.","journal-title":"Open Forum Infect Dis"},{"key":"740_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2022.108012","volume":"60","author":"X Chen","year":"2022","unstructured":"Chen X, Han J, Cai X, Wang S. Antimicrobial peptides: Sustainable application informed by evolutionary constraints. Biotechnol Adv. 2022;60:108012.","journal-title":"Biotechnol Adv"},{"key":"740_CR92","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/antibiotics9010024","volume":"9","author":"CH Chen","year":"2020","unstructured":"Chen CH, Lu TK. Development and challenges of antimicrobial peptides for therapeutic applications. Antibiotics. 2020;9:24.","journal-title":"Antibiotics"},{"key":"740_CR93","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0005-2736(99)00201-1","volume":"1462","author":"M Dathe","year":"1999","unstructured":"Dathe M, Wieprecht T. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim Biophys Acta. 1999;1462:71\u201387.","journal-title":"Biochim Biophys Acta"},{"key":"740_CR94","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/17425255.2017.1230200","volume":"13","author":"I Karaiskos","year":"2017","unstructured":"Karaiskos I, Souli M, Galani I, Giamarellou H. Colistin: still a lifesaver for the 21st century? Expert Opin Drug Metab Toxicol. 2017;13:59\u201371.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"740_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.616979","volume":"12","author":"GS Dijksteel","year":"2021","unstructured":"Dijksteel GS, Ulrich MMW, Middelkoop E, Boekema BKHL. Lessons learned from clinical trials using antimicrobial peptides (AMPs). Front Microbiol. 2021;12:616979.","journal-title":"Front Microbiol"},{"key":"740_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100954","volume":"68","author":"J Xuan","year":"2023","unstructured":"Xuan J, Feng W, Wang J, Wang R, Zhang B, Bo L, et al. Antimicrobial peptides for combating drug-resistant bacterial infections. Drug Resist Updates. 2023;68:100954.","journal-title":"Drug Resist Updates"},{"key":"740_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2021.691532","volume":"9","author":"T Sarkar","year":"2021","unstructured":"Sarkar T, Chetia M, Chatterjee S. Antimicrobial peptides and proteins: from nature\u2019s reservoir to the laboratory and beyond. Front Chem. 2021;9:691532.","journal-title":"Front Chem"},{"key":"740_CR98","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41573-019-0058-8","volume":"19","author":"N Mookherjee","year":"2020","unstructured":"Mookherjee N, Anderson MA, Haagsman HP, Davidson DJ. Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020;19:311\u201332.","journal-title":"Nat Rev Drug Discov"},{"key":"740_CR99","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.3390\/pharmaceutics13111795","volume":"13","author":"AO Fadaka","year":"2021","unstructured":"Fadaka AO, Sibuyi NRS, Madiehe AM, Meyer M. Nanotechnology-based delivery systems for antimicrobial peptides. Pharmaceutics. 2021;13:1795.","journal-title":"Pharmaceutics"},{"key":"740_CR100","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212858","volume":"14","author":"E Tenland","year":"2019","unstructured":"Tenland E, Pochert A, Krishnan N, Umashankar Rao K, Kalsum S, Braun K, et al. Effective delivery of the anti-mycobacterial peptide NZX in mesoporous silica nanoparticles. PLoS ONE. 2019;14:e0212858.","journal-title":"PLoS ONE"},{"key":"740_CR101","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1021\/acsabm.9b01154","volume":"3","author":"S Rigo","year":"2020","unstructured":"Rigo S, H\u00fcrlimann D, Marot L, Malmsten M, Meier W, Palivan CG. Decorating nanostructured surfaces with antimicrobial peptides to efficiently fight bacteria. ACS Appl Bio Mater. 2020;3:1533\u201343.","journal-title":"ACS Appl Bio Mater"},{"key":"740_CR102","doi-asserted-by":"publisher","DOI":"10.1007\/s10989-024-10648-0","author":"K Harini","year":"2024","unstructured":"Harini K, Girigoswami K, Thirumalai A, Girigoswami A. Polymer-based antimicrobial peptide mimetics for treating multi-drug resistant infections: therapy and toxicity evaluation. Int J Pept Res Ther. 2024. https:\/\/doi.org\/10.1007\/s10989-024-10648-0.","journal-title":"Int J Pept Res Ther"},{"key":"740_CR103","doi-asserted-by":"publisher","first-page":"36814","DOI":"10.1021\/acsami.8b16092","volume":"10","author":"M Chen","year":"2018","unstructured":"Chen M, Xie S, Wei J, Song X, Ding Z, Li X. Antibacterial micelles with vancomycin-mediated targeting and pH\/lipase-triggered release of antibiotics. ACS Appl Mater Interfaces. 2018;10:36814\u201323.","journal-title":"ACS Appl Mater Interfaces"},{"key":"740_CR104","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1021\/acs.biomac.9b00392","volume":"20","author":"D Pranantyo","year":"2019","unstructured":"Pranantyo D, Liu P, Zhong W, Kang E-T, Chan-Park MB. Antimicrobial peptide-reduced gold nanoclusters with charge-reversal moieties for bacterial targeting and imaging. Biomacromol. 2019;20:2922\u201333.","journal-title":"Biomacromol"},{"key":"740_CR105","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2147\/IDR.S160975","volume":"11","author":"P Jelinkova","year":"2018","unstructured":"Jelinkova P, Splichal Z, Jimenez AMJ, Haddad Y, Mazumdar A, Sur VP, et al. Novel vancomycin-peptide conjugate as potent antibacterial agent against vancomycin-resistant staphylococcus aureus. Infect Drug Resist. 2018;11:1807\u201317.","journal-title":"Infect Drug Resist."},{"key":"740_CR106","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijpharm.2018.12.035","volume":"558","author":"E Durack","year":"2019","unstructured":"Durack E, Mallen S, O\u2019Connor PM, Rea MC, Ross RP, Hill C, et al. Protecting bactofencin a to enable its antimicrobial activity using mesoporous matrices. Int J Pharm. 2019;558:9\u201317.","journal-title":"Int J Pharm"},{"key":"740_CR107","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/med.21879","volume":"42","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Hao W, Wang X, Ouyang J, Deng X, Yu H, et al. Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug-resistant infections. Med Res Rev. 2022;42:1377\u2013422.","journal-title":"Med Res Rev"},{"key":"740_CR108","doi-asserted-by":"crossref","unstructured":"Li W, O\u2019Brien\u2010Simpson NM, Holden JA, Otvos L, Reynolds EC, Separovic F, et al. Covalent conjugation of cationic antimicrobial peptides with a \u03b2\u2010lactam antibiotic core. Pept Sci. 2018;110:e24059.","DOI":"10.1002\/pep2.24059"},{"key":"740_CR109","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ebiom.2015.05.021","volume":"2","author":"L Lin","year":"2015","unstructured":"Lin L, Nonejuie P, Munguia J, Hollands A, Olson J, Dam Q, et al. Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant gram-negative bacterial pathogens. EBioMedicine. 2015;2:690\u20138.","journal-title":"EBioMedicine"},{"key":"740_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2020.104700","volume":"150","author":"A Jahangiri","year":"2021","unstructured":"Jahangiri A, Neshani A, Mirhosseini SA, Ghazvini K, Zare H, Sedighian H. Synergistic effect of two antimicrobial peptides, nisin and P10 with conventional antibiotics against extensively drug-resistant Acinetobacter baumannii and colistin-resistant Pseudomonas aeruginosa isolates. Microb Pathog. 2021;150:104700.","journal-title":"Microb Pathog"},{"key":"740_CR111","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","volume":"18","author":"M Paul","year":"2018","unstructured":"Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18:391\u2013400.","journal-title":"Lancet Infect Dis"},{"key":"740_CR112","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41522-023-00385-5","volume":"9","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zhang X, Liang S, Wang J, Zhu Y, Zhang W, et al. Bactericidal synergism between phage endolysin Ply2660 and cathelicidin LL-37 against vancomycin-resistant enterococcus faecalis biofilms. NPJ Biofilms Microbiomes. 2023;9:16.","journal-title":"NPJ Biofilms Microbiomes."},{"key":"740_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.12.009","author":"F Wagenlehner","year":"2021","unstructured":"Wagenlehner F, Lucenteforte E, Pea F, Soriano A, Tavoschi L, Steele VR, et al. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect. 2021. https:\/\/doi.org\/10.1016\/j.cmi.2020.12.009.","journal-title":"Clin Microbiol Infect"},{"key":"740_CR114","volume":"14","author":"Y Nishimura","year":"2022","unstructured":"Nishimura Y. Daptomycin-related rhabdomyolysis complicated by severe hyperkalemia and acute kidney injury. Cureus. 2022;14:e29764.","journal-title":"Cureus"},{"key":"740_CR115","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ijpharm.2017.12.039","volume":"537","author":"Z Gounani","year":"2018","unstructured":"Gounani Z, Asadollahi MA, Meyer RL, Arpanaei A. Loading of polymyxin B onto anionic mesoporous silica nanoparticles retains antibacterial activity and enhances biocompatibility. Int J Pharm. 2018;537:148\u201361.","journal-title":"Int J Pharm"},{"key":"740_CR116","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01940-24","volume":"69","author":"M Outeda-Garc\u00eda","year":"2025","unstructured":"Outeda-Garc\u00eda M, Garcia-Pose A, Guijarro-S\u00e1nchez P, Rodr\u00edguez-Coello A, B\u00e1ez-Barroso GA, Maceiras R, et al. The novel polymyxin analogue SPR206 exhibits higher activity than colistin against both colistin-susceptible and colistin-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2025;69:e0194024.","journal-title":"Antimicrob Agents Chemother"},{"key":"740_CR117","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10096-020-03945-1","volume":"40","author":"X Yu","year":"2021","unstructured":"Yu X, Pan J, Zhou Z, Wen X, Dai Y, Lin G, et al. TDM-guided medication of polymyxin B in a patient with CRKP-induced bloodstream infection: a case report. Eur J Clin Microbiol Infect Dis. 2021;40:201\u20134.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"740_CR118","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejmech.2013.10.065","volume":"71","author":"D Faccone","year":"2014","unstructured":"Faccone D, Veliz O, Corso A, Noguera M, Mart\u00ednez M, Payes C, et al. Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates. Eur J Med Chem. 2014;71:31\u20135.","journal-title":"Eur J Med Chem"},{"key":"740_CR119","unstructured":"A phase 3, randomized, vehicle-controlled, double-blind, multicenter study to evaluate the safety and efficacy of once-daily CLS001 topical gel versus vehicle administered for 12 weeks to subjects with papulopustular rosacea with a 4 week follow-up period [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT02576860. Accessed 25 July 2025."},{"key":"740_CR120","unstructured":"A phase 3 open-label extension study to evaluate the long-term safety of Omiganan topical gel in subjects with rosacea [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT02576847. Accessed 25 July 2025."},{"key":"740_CR121","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1111\/bcp.14181","volume":"86","author":"M Rijsbergen","year":"2020","unstructured":"Rijsbergen M, Rijneveld R, Todd M, Feiss GL, Kouwenhoven STP, Quint KD, et al. Results of phase 2 trials exploring the safety and efficacy of omiganan in patients with human papillomavirus-induced genital lesions. Br J Clin Pharmacol. 2020;86:2133\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"740_CR122","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/cbdd.13035","volume":"90","author":"SMS Ng","year":"2017","unstructured":"Ng SMS, Teo SW, Yong YE, Ng FM, Lau QY, Jureen R, et al. Preliminary investigations into developing all-D omiganan for treating mupirocin-resistant MRSA skin infections. Chem Biol Drug Des. 2017;90:1155\u201360.","journal-title":"Chem Biol Drug Des"},{"key":"740_CR123","unstructured":"A multicenter, open-label, randomized, active-controlled, parallel group, pivotal study to investigate the efficacy, safety and tolerability, and pharmacokinetics of murepavadin combined with one anti-pseudomonal antibiotic versus two anti-pseudomonal antibiotics in adult subjects with ventilator-associated bacterial pneumonia suspected or confirmed to be due to pseudomonas aeruginosa [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT03409679. Accessed 25 July 2025."},{"key":"740_CR124","unstructured":"A multicenter, open label, sponsor blinded, randomized, active controlled, parallel group, pivotal study to evaluate the efficacy, safety, and tolerability of murepavadin given with ertapenem versus an anti-pseudomonal-\u03b2-lactam-based antibiotic in adult subjects with nosocomial pneumonia suspected or confirmed to be due to pseudomonas aeruginosa [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT03582007. Accessed 25 July 2025."},{"key":"740_CR125","unstructured":"A multicenter, open label, sponsor blinded, randomized, active controlled, parallel group, pivotal study to evaluate the efficacy, safety, and tolerability of Murepavadin given with ertapenem versus an anti-pseudomonal-\u03b2-lactam-based antibiotic in adult subjects with nosocomial pneumonia suspected or confirmed to be due to Pseudomonas aeruginosa [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT03582007. Accessed 6 July 2025."},{"key":"740_CR126","unstructured":"A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of antimicrobial peptide PL-18 vaginal suppositories in healthy adult subjects [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT05340790. Accessed 25 July 2025."},{"key":"740_CR127","unstructured":"A randomized, double-blind, multicenter, superiority, placebo-controlled phase 3 study of Pexiganan cream 0.8% applied twice daily for 14 days in the treatment of adults with mild infections of diabetic foot ulcers [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT01590758. Accessed 24 Apr 2025."},{"key":"740_CR128","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9030128","volume":"9","author":"D Gomes","year":"2020","unstructured":"Gomes D, Santos R, Soares RS, Reis S, Carvalho S, Rego P, et al. Pexiganan in combination with nisin to control polymicrobial diabetic foot infections. Antibiotics. 2020;9:128.","journal-title":"Antibiotics"},{"key":"740_CR129","unstructured":"A phase IIa, randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of 3% LTX-109 compared to placebo for nasal decolonisation of staphylococcus aureus. [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT05889351. Accessed 25 July 2025."},{"key":"740_CR130","unstructured":"A double-blind, placebo-controlled, interventional parallel group study to evaluate the antiviral effect of a single nasal application of LTX-109 3% gel, in comparison to placebo gel, in subjects with COVID-19 infection. [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT04854928. Accessed 25 July 2025."},{"key":"740_CR131","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jbiotec.2016.10.010","volume":"239","author":"M Kudrimoti","year":"2016","unstructured":"Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, et al. Dusquetide: a novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016;239:115\u201325.","journal-title":"J Biotechnol"},{"key":"740_CR132","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/S0360-3016(03)01627-4","volume":"58","author":"A Trotti","year":"2004","unstructured":"Trotti A, Garden A, Warde P, Symonds P, Langer C, Redman R, et al. A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancy. Int J Radiat Oncol Biol Phys. 2004;58:674\u201381.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"740_CR133","unstructured":"A phase 2, open-label and single-blind study to evaluate the microbiology, safety and tolerability of C16G2 varnish and strip administered in multiple doses to adolescent and adult dental subjects [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT03196219. Accessed 25 Apr 2025."},{"key":"740_CR134","unstructured":"A\u00a0randomized, parallel-group, double-blind, placebo-controlled\u00a0study\u00a0of\u00a0DPK-060\u00a0to\u00a0investigate\u00a0clinical\u00a0safety\u00a0and\u00a0efficacy\u00a0in\u00a0patients\u00a0with\u00a0acute\u00a0external\u00a0otitis [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT01447017. Accessed 25 Apr 2025."},{"key":"740_CR135","unstructured":"A phase-IIa, double-blind, randomized, controlled study on the tolerability and early efficacy of hLF1-11 in hospitalized patients with bacteremia due to Staphylococcus epidermidis [Internet]. https:\/\/clinicaltrials.gov\/study\/NCT00509847. Accessed 25 Apr 2025."},{"key":"740_CR136","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/mmy\/myaa015","volume":"58","author":"DK Mercer","year":"2020","unstructured":"Mercer DK, Robertson JC, Miller L, Stewart CS, O\u2019Neil DA. NP213 (novexatin\u00ae): a unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile. Med Mycol. 2020;58:1064\u201372.","journal-title":"Med Mycol"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00740-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00740-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00740-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T04:48:07Z","timestamp":1761713287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00740-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":136,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00740-2","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"19 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by the Interdisciplinary Research Project of Hangzhou Normal University (2024JCXK02), the National Natural Science and Foundation of China (Grant no. 82241037 and 82170725), the Jiangxi Provincial Natural Science Foundation (20242BAB26114), the Zhejiang Provincial Natural Science Foundation of China (Grant no. LZ25H190001), and the Pioneer and Leading Goose R&D Program of Zhejiang (2023C03096).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All the authors contributed to the conception and design of the research. Material preparation, data collection, and analysis were carried out by Tiantian Lin, Xiaohui Yang, Jiasheng Song, and Jingxiang Wang. The first draft of the manuscript was written by Yuanzhi Ju, Luxi Weng, Huimin Su, Pengqin Chen, and Wuping Shuai. All the authors commented on previous versions of the manuscript. All the authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}}]}}